Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Pfizer to Sell Stake in Haleon Following GSK De-Merger
Pfizer to Sell Stake in Haleon Following GSK De-Merger
Next month, GlaxoSmithKline will complete its de-merger, forming two companies, New GSK, a pharma-focused business, and Haleon, a stand-alone consumer health operation. 
With $600M in Funding, Ultima is Removing Cost Barriers to Genomic Research
With $600M in Funding, Ultima is Removing Cost Barriers to Genomic Research

How much could a human genome cost? The answer is $100, according to newly unveiled biotech company Ultima Genomics.

BMS Preps Lupus Treatment to Become Third New Launch of 2022
BMS Preps Lupus Treatment to Become Third New Launch of 2022
Bristol Myers Squibb (BMS) has announced late-breaking data showing deucravacitinib significant efficacy at the primary endpoint for the treatment of systemic lupus erythematosus (SLE). ...
Britain’s GSK to buy Affinivax for up to $3.3 billion in vaccines push
Britain’s GSK to buy Affinivax for up to $3.3 billion in vaccines push
GSK said today it would pay up to $3.3 billion to acquire privately held biopharma firm Affinivax to bolster its vaccine pipeline, a key area of focus as the British drugmaker prepares to separate ...
US FDA declines to approve Eton Pharma’s anti-seizure drug
US FDA declines to approve Eton Pharma’s anti-seizure drug
Eton Pharma said yesterday the US Food and Drug Administration (FDA) declined to approve its anti-seizure drug lamotrigine, sending the drugmaker’s shares down 13 per cent in extended trading. ...
FDI inflow into pharma sector declines 5% in 2021-22
FDI inflow into pharma sector declines 5% in 2021-22
After recording a 200 per cent growth in Foreign Direct Investment (FDI) equity inflow into the sector in the previous year, foreign equity infusion into the drugs and pharmaceutical industry in In...
European Commission Conditionally Approves Janssen and Legend Biotech’s Carvykti for Multiple Myeloma
European Commission Conditionally Approves Janssen and Legend Biotech’s Carvykti for Multiple Myeloma
The European Commission has given conditional approval to Janssen’s chimeric antigen receptor (CAR) T-cell therapy Carvykti (ciltacabtagene autoleucel) for relapsed and refractory multiple myelo...
Study: mRNA COVID-19 Vaccines Perform Better Than Viral Vector Vaccines
Study: mRNA COVID-19 Vaccines Perform Better Than Viral Vector Vaccines
Research suggests that individuals receiving a vaccine, such as ones from AstraZeneca and Johnson & Johnson, were more vulnerable to infection by new variants. ...
Nirogacestat Improves Progression-Free Survival in Adults With Progressing Desmoid Tumors
Nirogacestat Improves Progression-Free Survival in Adults With Progressing Desmoid Tumors

Treatment with nirogacestat resulted in a 71% reduction in the risk of disease progression among adults with progressing desmoid tumors.

Hyundai Bioscience to seek fast track processing from US FDA for oral antiviral medicine, CP-COV03, to treat monkeypox Seoul, South Korea
Hyundai Bioscience to seek fast track processing from US FDA for oral antiviral medicine, CP-COV03, to treat monkeypox Seoul, South Korea
Hyundai Bioscience, a biotechnology company that developed and commercialized bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body, has decide...
Servier Gets Expanded FDA Approval of Tibsovo for IDH1-Mutated AML
Servier Gets Expanded FDA Approval of Tibsovo for IDH1-Mutated AML
The FDA has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) in combination with Bristol Myers Squibb’s Onureg (azacitidine) to treat patients 75 years and older with newly diagnosed iso...
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholi...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand